• 2002

Company Description

Xigen, a biopharmaceutical company, develops therapeutics to inhibit intracellular protein interactions.

Xigen SA is a private Swiss biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) in Switzerland. Dr. Christophe Bonny, CEO and co-founder, is a renowned molecular biologist with over a decade's research expertise on intracellular peptides and signalling.